Novo Nordisk raises outlook fueled by weight loss drug demand

Novo Nordisk raised its 2024 outlook on Thursday and delivered better-than-expected first-quarter profits as the Danish drugmaker races to boost output of its Wegovy weight-loss drug and fend off competition from rival Eli Lilly.

Novo is currently the most valuable company in Europe by market capitalization, worth some 540.4 billion euro ($576.44 billion) before earnings on Thursday, on the back of Wegovy’s popularity.

The group’s shares were down 2.3 percent at 0713 GMT, a small dent when they have risen around 260 percent since launching Wegovy in the United States in June 2021.

The company is spending billions to boost its manufacturing capacity to meet runaway demand for the weekly Wegovy injection. It increased the amount of Wegovy it supplied to the US market in the first quarter, CEO Lars Fruergaard Jorgensen told a media call.

About 27,000 new patients in the US are now starting on the weekly injection each week, Jorgensen said. “This is really a very nice volume ramp, as we were planning for,” he said. That is a four-fold increase in the US supply of starter doses since December.

A year ago, Novo began limiting the number of US patients who can start treatment by reducing the supply of the lowest three doses of the appetite-suppressing weekly injection.

In January, Novo said it was more than doubling supply of lower strength or “starter” Wegovy doses in the US that month compared with recent ones. Still, shortages in the US persist.

The modest increase to the outlook and forecast-beating results underscore Wegovy’s success and Novo’s lead in the fast-growing obesity drug market. Novo’s growth has nonetheless been held back by its ability to ramp up production quickly enough to meet demand.

Competition

The company is facing fierce competition from US rival Eli Lilly as it rolls out its Zepbound therapy in new markets. It launched in the United States in December and in Germany, Poland and Britain this year.

As volume and competition have increased, the price of Wegovy came “slightly down” in the first three months of the year, Chief Financial Officer Karsten Munk Knudsen said.

Novo said it now expects sales growth this year of between 19 percent and 27 percent in local currencies, compared to the previously guided range for 18 percent to 26 percent growth.

Operating profit growth this year is now seen at between 22 percent and 30 percent in local currencies, slightly up from its previous forecast of 21 percent to 29 percent.

“Considering the ongoing supply constraints, Novo delivered a decent set of numbers,” said Markus Manns, a portfolio manager at Union Investment in Germany and a Novo shareholder.

“The guidance raise was only modest, but most people didn’t expect an increase so early in the year,” he told Reuters.

The company reported first-quarter earnings before interest and taxation (EBIT) of 31.8 billion Danish crowns ($4.57 billion), above the 29 billion forecast by analysts in a LSEG poll this week and up 27 percent from a year ago.